Search results
Monty Don slams Chelsea Flower Show judges as surprise entry wins top prize
Daily Express· 3 days agoUla Maria’s Japanese-inspired forest garden designed for people suffering from muscle wastage won...
Standup Comedian Dies of Cancer: Diane Ford Was 68
popculture.com· 2 days agoPopular stand-up comedian Diane Ford has died. Ford, headlined HBO specials and A&E's An Evening at the Improv, passed away of cancer in Sarasota,...
JPMorgan maintains overweight rating on Dynatrace with $60 target By Investing.com
Investing.com· 4 days agoOn Monday, JPMorgan (NYSE:JPM) reiterated its Overweight rating with a $60.00 price target for...
Biotech Soars As Its Biggest Drug 'Lives To Fight Another Day'
Investor's Business Daily· 4 days agoTranslarna has a conditional approval in Europe to treat patients with a muscle-wasting disease...
Pediatric Patients Transform Into Superheroes, Complete with Costumes and Movie Posters (Exclusive)
People via Yahoo News· 5 days agore storytellers, and these little people have amazing stories. And if we can help them get through...
PTC Therapeutics (NASDAQ:PTCT) Upgraded at Raymond James
ETF DAILY NEWS· 4 days agoPTC Therapeutics (NASDAQ:PTCT – Get Free Report) was upgraded by Raymond James from an “underperform” rating to a “market perform” rating in a research report issued on Monday, Marketbeat reports ...
Innovative Thinking Could Make New Sickle Cell Treatments More Accessible
Scientific American· 2 days agoLast fall, to great fanfare, US regulators approved two gene therapies for sickle cell disease, and...
Oxana Beskrovnaya Sells 2,705 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock
ETF DAILY NEWS· 5 days agoDyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) insider Oxana Beskrovnaya sold 2,705 shares of the stock in a transaction that occurred on Thursday, May 16th. Following the completion ...
The 2030 Millionaire's Club: 3 Biotech Stocks to Buy Now
InvestorPlace· 1 day agoWith the interest cuts coming up, it’s an ideal time to consider loading up on the top biotech...
Sarepta Therapeutics (NASDAQ:SRPT) PT Raised to $179.00
ETF DAILY NEWS· 5 days agoSarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its target price hoisted by Mizuho from $145.00 to $179.00 in a report issued on Friday, Benzinga reports. The firm presently has a “ ...
